Part of the guide: Q1 FY27 results (April to June 2026): company results we have covered
results decoderDr Lal PathLabs Q1 FY27: revenue ₹798 crore, up 19.1%; net profit ₹170 crore
The diagnostics company reported consolidated revenue growth of 19.1% and EBITDA growth of 28.7% for the June 2026 quarter, and declared an interim dividend of ₹5 per share.
Dr Lal PathLabs reported consolidated revenue of ₹798 Cr for the quarter ended 30 June 2026 (Q1 FY27), up 19.1% from a year earlier, in a press release dated 24 July 2026.
Key figures (consolidated)
| Metric | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | ₹798 Cr | ₹670 Cr | +19.1% |
| EBITDA margin | 31.0% | n/a | EBITDA +28.7% |
| Profit before tax | ₹229 Cr | ₹181 Cr | n/a |
| Net profit (PAT) | ₹170 Cr | ₹134 Cr | +26.9% (computed) |
| PAT margin | 21.4% | 20.0% | n/a |
| Earnings per share | ₹10.1 | ₹7.9 | n/a |
Dividend and balance sheet
- The company declared an interim dividend of 50%, or ₹5 per share.
- Cash and cash equivalents were ₹1,693 Cr as of 30 June 2026.
Acquisitions announced
- An 80% equity stake in Sunshine Healthcare Limited, Ghana, which is in the diagnostic business, for a consideration not exceeding GHS 45.6 million.
- A 30% equity stake in Neuome Technologies Private Limited, which works on sample preservation and biobanking solutions, for a consideration not exceeding ₹3.5 Cr.
Basis of these figures
The figures are consolidated and unaudited, and are subject to the limited review described in the company’s financial results filing. EBITDA is as defined by the company. Read the full press release.